Details

Autor(en) / Beteiligte

• Yorgancıoğlu, Arzu
• Aksu, Kurtuluş
• Naycı, Sibel Atış
• Ediger, Dane
• Mungan, Dilşad
• Gül, Umut
• Beekman, Maarten J. H. I.
• Kızılırmak, Deniz
• Altıntaş, Nejat
• Bulut, İsmet
• Çağatay, Tülin
• Gemicioğlu, Bilun
• İnce, Özgür
• Oğuzülgen, Kıvılcım
• Kalpaklıoğlu, Füsun
• Baççıoğlu, Ayşe
• Aksu, Funda
• Altuntaş, Murat
• Erkekol, Ferda Öner
• Karakaya, Gül
• Kalyoncu, Ali Fuat
• Damadoğlu, Ebru
• Hanta, İsmail
• Altunok, Ersoy
• Özer, Adviye
• Yuluğ, Demet Polat
• Gülbaş, Gazi
• Süerdem, Mecit
• Yormaz, Burcu
• Ceylan, Emel
• Erge, Duygu
• Çilli, Aykut
• Doğan, Berat Celil
• Erel, Fuat
• Sevinç, Can
• Anar, Ceyda
• Pekbak, Gülseren
• Erbay, Müge

Titel

Short-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III

Ist Teil von

• BMC pulmonary medicine, 2022-06, Vol.22 (1), p.1-216, Article 216

Ort / Verlag

London: BioMed Central

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Abstract Background Over-reliance on short-acting β 2 -agonists (SABAs) is associated with poor asthma outcomes. However, the extent of SABA use in Turkey is unclear owing to a lack of comprehensive healthcare databases. Here, we describe the demographics, disease characteristics and treatment patterns from the Turkish cohort of the SABA use IN Asthma (SABINA) III study. Methods This observational, cross-sectional study included patients aged ≥ 12 years with asthma from 24 centres across Turkey. Data on sociodemographics, disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by the 2017 Global Initiative for Asthma [GINA]) and practice type (primary/specialist care). The primary objective was to describe SABA prescription patterns in the 12 months prior to the study visit. Results Overall, 579 patients were included (mean age [standard deviation; SD]: 47.4 [16.1] years; 74.3% female), all of whom were treated by specialists. Most patients had moderate-to-severe asthma (82.7%, GINA steps 3–5), were overweight or obese (70.5%), had high school or university/post-graduate education (51.8%) and reported fully reimbursed healthcare (97.1%). The mean (SD) asthma duration was 12.0 (9.9) years. Asthma was partly controlled/uncontrolled in 56.3% of patients, and 46.5% experienced ≥ 1 severe exacerbation in the preceding 12 months. Overall, 23.9% of patients were prescribed ≥ 3 SABA canisters in the previous 12 months (considered over-prescription); 42.9% received no SABA prescriptions. As few patients had mild asthma, only 5.7% were prescribed SABA monotherapy. Therefore, most patients (61.5%) were prescribed SABA in addition to maintenance therapy, with 42.8% receiving ≥ 3 SABA canisters in the previous 12 months. Inhaled corticosteroids (ICS), ICS + a long-acting β-agonist fixed-dose combination and oral corticosteroids were prescribed to 14.5%, 88.3% and 28.5% of all patients, respectively. Additionally, 10.2% of patients purchased SABA over the counter, of whom 27.1% purchased ≥ 3 canisters in the preceding 12 months. Conclusions Despite all patients being treated by specialists and most receiving fully reimbursed healthcare, nearly a quarter of patients received prescriptions for ≥ 3 SABA canisters in the previous 12 months. This highlights a public health concern and emphasizes the need to align clinical practices with the latest evidence-based recommendations.